PATAS
PATAS, the lead therapeutic compound
PATAS is an innovative peptide that targets a specific protein-protein interaction of ALMS1 in the adipocyte. PATAS has been successfully shown in pre-clinical studies to trigger insulin-independent glucose absorption in the adipocyte, resulting in a long-term beneficial impact through modifications in lipid signalling.
Significant beneficial systemic effects have been established in pre-clinical studies both in vitro and in vivo. PATAS has demonstrated remarkable anti-diabetic effects, an improvement of pancreatic functions associated with increased insulin secretion, while reducing comorbidities like liver steatosis, fibrosis, cardiovascular complications, and most notably, has a positive impact on ceramides.
PATAS's benefits
By restoring glucose absorption in the diseased adipocyte, PATAS gives back to the adipocyte its physiological glucose-based cellular fuel tropism.
PATAS clinically relevant effects are:
- Anti-diabetic
- Significant reduction of insulin resistance
- Anti-non-alcoholic fatty liver disease (NAFLD)
- Anti-fibrotic
- Improves pancreatic function associated with increased insulin secretion and reduced pancreatic plaque
- Improves cardiovascular function via improving ceramide scores
